LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

Search

IQVIA Holdings Inc

Geschlossen

Branche Gesundheitswesen

209.18 1.27

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

208.77

Max

210.14

Schlüsselkennzahlen

By Trading Economics

Einkommen

-78M

285M

Verkäufe

90M

3.9B

KGV

Branchendurchschnitt

28.89

104.138

EPS

2.84

Gewinnspanne

7.308

Angestellte

87,000

EBITDA

-12M

856M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+24.13 upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-4.9B

37B

Vorheriger Eröffnungskurs

207.91

Vorheriger Schlusskurs

209.18

Nachrichtenstimmung

By Acuity

50%

50%

167 / 389 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

IQVIA Holdings Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Nov. 2024, 22:50 UTC

Heiße Aktien

Stocks to Watch: Nvidia, Intel, Sherwin-Williams, Dow, Nuwellis

1. Nov. 2024, 22:43 UTC

Wichtige Markttreiber

Nvidia, Sherwin-Williams Shares Up on Addition to DJIA

1. Nov. 2024, 22:13 UTC

Wichtige Markttreiber

Chewy Up 5% on S&P MidCap 400 Inclusion

1. Nov. 2024, 21:39 UTC

Ergebnisse

Insurance Company Chubb Projects Up to $300 Million Pre-Tax Loss on Hurricane

2. Nov. 2024, 13:53 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2. Nov. 2024, 13:44 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. Nov. 2024, 13:00 UTC

Ergebnisse

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2. Nov. 2024, 12:58 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. Nov. 2024, 12:48 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2. Nov. 2024, 12:32 UTC

Ergebnisse

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2. Nov. 2024, 12:28 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. Nov. 2024, 12:17 UTC

Ergebnisse

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q EPS $18272.00 >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q BNSF Operating Earnings $1.38B >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Berkshire Hathaway Energy Company Operating Earnings $1.63B >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Insurance-Underwriting Operating Earnings $750M >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Other Operating Loss $877M >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Insurance-Investment Income Operating Earnings $3.66B >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Net $26.25B >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Other Controlled Businesses Operating Earnings $3.34B >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Non-Controlled Businesses Operating Earnings $199M >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Operating Earnings $10.09B >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Investment, Derivative Gains $16.16B >BRKA

2. Nov. 2024, 09:30 UTC

Top News

Awful Jobs Report Aside, the Economy Is Still Strong -- Heard on the Street -- WSJ

2. Nov. 2024, 08:20 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

2. Nov. 2024, 08:20 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

1. Nov. 2024, 22:51 UTC

Ergebnisse

Correction to Nvidia to Replace Intel in Dow Jones Industrial Average Article -- WSJ

1. Nov. 2024, 22:00 UTC

Top News
Ergebnisse

Nvidia to Replace Intel in Dow Jones Industrial Average. Sherwin-Williams Also Joins. -- WSJ

1. Nov. 2024, 21:29 UTC

Top News
Ergebnisse

Exxon and Chevron Feel Brunt of Cheaper Oil -- 2nd Update

1. Nov. 2024, 21:24 UTC

Ergebnisse

Insurance Company Chubb Projects Up to $300M Pre-Tax Loss on Hurricane

Peer-Vergleich

Kursveränderung

IQVIA Holdings Inc Prognose

Kursziel

By TipRanks

24.13% Vorteil

12-Monats-Prognose

Durchschnitt 259.64 USD  24.13%

Hoch 279 USD

Tief 235 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für IQVIA Holdings Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

12

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

200.3 / 214.63Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

167 / 389 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über IQVIA Holdings Inc

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides critical information, technology solutions and real-world insights and services to the Company's life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, providing outsourced clinical research and clinical trial related services. The Contract Sales & Medical Solutions segment provides health care provider, including contract sales and patient engagement services to both biopharmaceutical clients and the broader healthcare market. The Company protects individual patient privacy. The Company conducts business in more than 100 countries.